| 0.677 0.021 (3.2%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.16 | 1-year : | 1.48 |
| Resists | First : | 1 | Second : | 1.26 |
| Pivot price | 1.02  |
|||
| Supports | First : | 0.56 | Second : | 0.47 |
| MAs | MA(5) : | 0.87 |
MA(20) : | 1.06 |
| MA(100) : | 1.23 |
MA(250) : | 1.7 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 20.3 |
D(3) : | 21  |
| RSI | RSI(14): 22.3 |
|||
| 52-week | High : | 2.98 | Low : | 0.56 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ INO ] has closed below the lower bollinger band by 6.5%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ INO ] is to continue within current trading range. It is unclear right now based on current values. 74.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.68 - 0.68 | 0.68 - 0.69 |
| Low: | 0.61 - 0.62 | 0.62 - 0.62 |
| Close: | 0.67 - 0.68 | 0.68 - 0.68 |
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
Fri, 31 Jul 2026
INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally - Stocktwits
Fri, 31 Jul 2026
Vanguard Capital Management (INO) discloses 5.05% beneficial stake in Inovio stock - Stock Titan
Fri, 31 Jul 2026
Inovio Pharmaceuticals Secures $18.3 Million Stock-and-Warrant Offering With Piper Sandler - TradingView
Thu, 30 Jul 2026
INOVIO Announces Proposed Public Offering - Finviz
Mon, 13 Jul 2026
INOVIO PHARMACEUTICALS, INC. SEC Filing (Jul 13, 2026) - Stock Titan
Thu, 14 May 2026
Inovio: All Eyes On INO-3107 As Binary FDA Decision Looms (NASDAQ:INO) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 82 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 47.2 (%) |
| Shares Short | 14,570 (K) |
| Shares Short P.Month | 16,200 (K) |
| EPS | -1.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.09 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -76.4 % |
| Return on Equity (ttm) | -296.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.64 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -83 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -0.43 |
| PEG Ratio | 0 |
| Price to Book value | 7.52 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|